LakeShore Biopharma Co., Ltd. reported receiving arbitration awards on January 21-22, 2026, totaling RMB446 million in claims against its subsidiaries, which it disputes and will challenge. Additionally, an ongoing criminal investigation relates to previous fraudulent litigation activities tied to former chairman Yi Zhang.